Sacharin R, Taylor T, Chasseaud L F
Int J Vitam Nutr Res. 1977;47(1):68-74.
Plasma and whole blood concentrations of ascorbate have been measured after administration of 1000 mg of the vitamin as standard or sustained-release capsule formulations to human subjects. A peak of mean whole blood and plasma concentrations of 8.5 mug/ml and 5.7 mug/ml respectively (corrected for predose concentrations of "endogenous" ascorbate) occurred at 12 h and 6 h respectively after administration of a sustained-release formulation. After administration of a standard formulation, the peak of mean whole blood and plasma concentrations of 9.4 mug/ml and 8.6 mug/ml respectively occurred at 4 h. In whole blood, mean concentrations of ascorbate declined with a half-life of about 34 h. The bioavailability of ascorbate from the sustained-release formulation was 149% and 180% of that from the standard formulation by calculation from whole blood and plasma concentration data respectively.
在给人体受试者服用1000毫克标准或缓释胶囊制剂形式的维生素后，已对血浆和全血中的抗坏血酸浓度进行了测量。服用缓释制剂后，全血和血浆平均浓度分别在给药后12小时和6小时达到峰值，分别为8.5微克/毫升和5.7微克/毫升（针对“内源性”抗坏血酸的给药前浓度进行了校正）。服用标准制剂后，全血和血浆平均浓度峰值分别为9.4微克/毫升和8.6微克/毫升，出现在4小时。在全血中，抗坏血酸的平均浓度以约34小时的半衰期下降。根据全血和血浆浓度数据计算，缓释制剂中抗坏血酸的生物利用度分别是标准制剂的149%和180%。
